Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
AstraZeneca
AstraZeneca
Activities:
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Finance
AstraZeneca completes acquisition of Amolyt Pharma
The $1.05bn acquisition has been completed, and will bolster AstraZeneca's rare endocrine disease pipeline
Regulatory
Tagrisso plus chemo for advanced lung cancer approved in the EU
Tagrisso and chemotherapy improved progression-free survival by 38% when compared with monotherapy alone
Drug Delivery
Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle
AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Research & Development
BenevolentAI and AstraZeneca collaboration leads to novel lupus target discovery
The novel target will be added to AstraZeneca's drug development pipeline for lupus, an autoimmune disease with significant unmet needs in the patient population
Regulatory
AstraZeneca’s Tagrisso plus chemo for EGFR-mutated lung cancer approved in Japan
The approval comes off the back of the positive Phase III FLAURA2 trial results, showing a significant improvement in PFS compared with Tagrisso monotherapy
Regulatory
Truqap-Faslodex combination receives EU approval for ER+ breast cancer
The approval stems from the positive results from the CAPItello-291 Phase III trial
Regulatory
FDA approves AstraZeneca's Imfinzi-chemo combo for advanced endometrial cancer in US
Imfinzi reduced the risk of disease progression and death compared to chemotherapy alone by 58% in the recent Phase III DUO-E trial
Subscribe now